MedTrace Logo

Evaluation of Predictive Risk Factors of Chemotherapy-induced Nausea and Vomiting

NCT01993381 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2017-06-14

No results posted yet for this study

Summary

The most common toxicity of chemotherapy is nausea and vomiting, and appropriate management of these toxicities can help patients improve tolerance for chemotherapy. Anti-emetics including dopamine antagonist, serotonin antagonist, and substance P antagonist administered to patients according to emetogenic risk of chemotherapeutic drugs. However, patients don't always experience same nausea and vomiting for the same drugs. Therefore, it is important to determine the biomarker to predict chemotherapy-induced nausea and vomiting. Some biomarkers studies were done during the chemotherapy. However it is not definite evidence of relations between biomarkers and chemotherapy. We will hope to find any predictive biomarker of CINV.

Conditions

  • Chemotherapy-induced Nausea and Vomiting

Sponsors & Collaborators

  • The Catholic University of Korea

    lead OTHER

Principal Investigators

  • Byoungyong Shim, M.D., Ph.D. · Department of medical oncology, The Catholic University of Korea

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2017-11-30
Completion
2017-11-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01993381 on ClinicalTrials.gov